Login to Your Account

Compounded Avastin Recall Good News for Regeneron

By Mari Serebrov
Washington Editor

Thursday, March 21, 2013
The FDA raised another safety flag over the continued off-label use of Avastin Wednesday when it issued a MedWatch alerting physicians of a recall of the compounded cancer drug intended as an unapproved treatment for wet age-related macular degeneration (AMD). While that's bad news for compounders, it could be good news for Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription